MEI Historical Income Statement
| MEIP Stock | USD 2.81 0.01 0.36% |
Historical analysis of MEI Pharma income statement accounts such as Gross Profit of 51.8 M can show how well MEI Pharma performed in making a profits. Evaluating MEI Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of MEI Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining MEI Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether MEI Pharma is a good buy for the upcoming year.
MEI |
About MEI Income Statement Analysis
MEI Pharma Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to MEI Pharma shareholders. The income statement also shows MEI investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
MEI Pharma Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of MEI Pharma. It is also known as MEI Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from MEI Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into MEI Pharma current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.At this time, MEI Pharma's Income Before Tax is relatively stable compared to the past year. As of 11/22/2024, Net Income is likely to grow to about 18.7 M, while Total Operating Expenses is likely to drop slightly above 31.1 M.
MEI Pharma income statement Correlations
Click cells to compare fundamentals
MEI Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MEI Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 57.1M | 44.3M | 37.2M | 284K | 326.6K | 310.3K | |
| Selling General Administrative | 16.7M | 24.4M | 30.5M | 33.1M | 23.3M | 24.5M | |
| Total Revenue | 28.9M | 25.5M | 40.7M | 48.8M | 65.3M | 68.6M | |
| Gross Profit | 26.2M | 24.1M | 39.5M | 47.0M | 49.3M | 51.8M | |
| Other Operating Expenses | 53.5M | 95.2M | 116.2M | 85.6M | 50.8M | 32.7M | |
| Operating Income | (24.5M) | (69.7M) | (75.5M) | (36.8M) | 14.5M | 15.3M | |
| Ebit | (1.7M) | (60.4M) | (76.4M) | (38.6M) | 26.0M | 27.3M | |
| Research Development | 34.1M | 69.4M | 85.6M | 52.5M | 16.6M | 20.2M | |
| Ebitda | (1.6M) | (60.1M) | (75.2M) | (36.8M) | 26.4M | 27.7M | |
| Total Operating Expenses | 50.8M | 93.8M | 116.2M | 85.6M | 34.8M | 31.1M | |
| Income Before Tax | (46.0M) | (50.6M) | (54.5M) | (31.8M) | 17.8M | 18.7M | |
| Net Income | (46.0M) | (41.3M) | (54.5M) | (31.8M) | 17.8M | 18.7M | |
| Cost Of Revenue | 2.7M | 1.4M | 1.2M | 1.8M | 16.0M | 16.8M | |
| Total Other Income Expense Net | (21.5M) | 19.1M | 21.0M | 4.9M | 3.2M | 4.6M | |
| Depreciation And Amortization | 109K | 285K | 1.2M | 1.8M | 383K | 402.2K | |
| Net Income From Continuing Ops | (46.0M) | (50.6M) | (54.5M) | (31.8M) | 17.8M | 18.7M | |
| Non Operating Income Net Other | (9.1M) | 29.4M | (21.5M) | 19.1M | 22.0M | 23.1M | |
| Net Income Applicable To Common Shares | (46.0M) | (50.6M) | (54.5M) | (31.8M) | (28.7M) | (30.1M) | |
| Interest Income | 1.4M | 510K | 284K | 3.3M | 3.3M | 3.4M | |
| Net Interest Income | 1.4M | 510K | 284K | 3.3M | 3.3M | 3.4M | |
| Reconciled Depreciation | 109K | 285K | 326K | 386K | 383K | 234.7K |
Pair Trading with MEI Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with MEI Stock
Moving against MEI Stock
| 0.61 | NTRB | Nutriband | PairCorr |
| 0.6 | BMEA | Biomea Fusion | PairCorr |
| 0.58 | VRDN | Viridian Therapeutics | PairCorr |
| 0.44 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.35 | ALVO | Alvotech | PairCorr |
The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.
The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.